secwatch.observer — SEC 8-K summary
======================================

Issuer:     Ernexa Therapeutics Inc. (ERNA)
CIK:        0000748592
Form:       8-K
Filed at:   2024-09-23T23:59:59+00:00
Accession:  0001493152-24-037815
Event type: regulatory
Sentiment:  negative
Materiality: 0.80
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

Eterna Therapeutics receives Nasdaq delisting notice for failure to regain compliance with equity rule
--------------------------------------------------------------------------------

- On Sept 17, 2024, Nasdaq determined Eterna did not meet the extension terms to demonstrate compliance with the Minimum Stockholders' Equity Rule (stockholders' equity < $2.5M as of Dec 31, 2023).
- Trading of ERNA common stock will be suspended on Sept 26, 2024 unless a hearing request is filed by Sept 24, 2024.
- Company intends to timely request a hearing with Nasdaq's Hearings Panel to appeal the determination; a stay will be in effect pending decision.
- Hearings typically scheduled 30-45 days after request; panel decision within 30 days of hearing; no assurance of success.
- If appeal fails or no request, a Form 25-NSE will be filed, removing ERNA from Nasdaq listing and registration.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/748592/000149315224037815/0001493152-24-037815-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/748592/000149315224037815/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-037815

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer